Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”) announces today that on May 7, 2026, it disposed of 50,000 Class A units of Canso Credit Income Fund (“CCIF” or the...
-
INFORMATIONS RÉGLEMENTÉESLe 8 mai 2026, 22:05h CET / 16:05h ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgique(ci-après la « Société ») Invitation à...
-
REGULATED INFORMATIONMay 8, 2026, 10:05pm CET / 4:05pm ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to...
-
FREDERICK, Md., May 08, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary...
-
Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.
-
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company...
-
ATHENS, Greece, May 08, 2026 (GLOBE NEWSWIRE) -- Dynagas LNG Partners LP (the “Partnership”) (NYSE: “DLNG”), an owner and operator of LNG carriers, today announced that its Board of Directors has...
-
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted...
-
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina...
-
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)